Today: July 23, 2017, 10:53 am
  
Business

XBiotech Announces Outcome of EMA's Oral Explanation Meeting

PR-Inside.com: 2017-04-21 00:58:01

AUSTIN, Texas, April 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative "trend" vote after meeting with the Company to discuss the "Day 180 List of Outstanding Issues" related to the Company's marketing authorization application (MAA) for its candidate antibody for the treatment of colorectal cancer. A negative trend vote means it is unlikely that a positive Committee for Medicinal Products for Human Use (CHMP) opinion related to the Company's MAA will be attained at the formal decision vote scheduled in May, and that additional steps would need to be taken to potentially gain marketing approval.

At the Oral Explanation meeting, per EMA protocol, the Company gave a 20 minute presentation and had a Q&A session with CHMP members regarding the MAA for its candidate therapy to treat advanced colorectal cancer (data presented by the Company will be filed with the SEC in a Form 8-K and will be available on the SEC's website at www.sec.gov). The Oral Explanation format is intended to provide an opportunity for the Company to clarify data in support of marketing authorization.

The key outstanding issues are related to clinical relevance of the therapy in the indication and quality assurance related matters. The meeting, however, focused on outstanding clinical relevance issues.

John Simard, President & CEO of the Company, stated, "We are disappointed by the outcome of the meeting. We believe that the data speak in a clear and resounding voice to clinical relevance of a new antibody therapy in advanced colorectal cancer. We believe that findings from our Phase III study show that we have developed an important endpoint and methodology to evaluate anti-cancer therapy in advanced stage disease and that our monoclonal antibody represents a breakthrough treatment in patients with advanced colorectal cancer. The EMA marketing authorization application procedure enables the appeal of negative decisions from the oral explanation. We may seek access to this process at the appropriate time."

About True Human(TM) Therapeutic Antibodies

XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire




# 902 Words
Related Articles
More From The Author
Murphy USA Announces Pricing of Notes Offering
EL DORADO, Arkansas, April 20, 2017 - Murphy USA (NYSE: MUSA) announced today that it has priced its previously announced [..]
Tech Mahindra Expands Relationship with Covisint to [..]
Global Partnership Drives Digital Business Transformation by Securely Connecting Complete Ecosystems of People, Systems and [..]
Heineken Holding N.V. Annual General Meeting of [..]
Amsterdam, 20 April 2017 - Heineken Holding N.V. announced today that its Annual General Meeting of Shareholders (AGM) has adopted [..]
Heineken N.V. Annual General Meeting adopts all [..]
Amsterdam, 20 April 2017 - Heineken N.V. announced today that its Annual General Meeting (AGM) has adopted all proposals on [..]
Head to Iceland on the Land Rover [..]
Customers of Mytyres.co.uk : This Smart News Release features multimedia. View the full release here. During the six-day Experience [..]
 
More From Business
Rakhi.giftalove.com: The Most Apt Space to Send [..]
Rakhi.giftalove.com is one the best platform to send Rakhi to Hyderabad and to any other location of the world. In [..]
Sendrakhi.com Delivering Rakhis throughout the Country
New Delhi, Delhi, 20-July-17: Online shopping for Raksha Bandhan has caught up a great pace with more and more people [..]
28th Hong Kong Book Fair Opens with [..]
HONG KONG, July 19, 2017 - (ACN Newswire) - The 28th Hong Kong Book Fair opened today and will run [..]
Rakhi.in High Achievers in the International Market
New Delhi, Delhi, 18-July-17: Rakhi.in has tackled a lot of challenges head on to provide its customers with the best [..]
Max Lami Skate Wear Clothing Announces Pop-up [..]
After a successful brand launch on July 10th 2017, Max Lami Clothing is now looking to open pop –up shops [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.